AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06799429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised in-person group
Description: Individually prescribed and directed/supervised by a fitness trainer in-person, multi-mode exercise 2 x a week for 30-60 minutes The fitness trainer is with the participant while they exercise.
Study NCT06799429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitored distance group
Description: Individually prescribed ulti-mode exercise 2 x a week for 30-60 minutes. Written plan/feedback and support by phone/text or email is provided by a fitness trainer who is not present with the participant when they exercise.
Study NCT06798662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Pulsed Radiofrequency (PRF)
Description: A high-frequency linear ultrasound transducer will be used for this procedure. The transducer will be placed transversely over the target rib area to obtain a clear visualization of the rib, intercostal muscles, and pleura. The entry point for needle insertion will be selected 1-2 cm inferior to the inferior border of the target rib. Using a 22G radiofrequency (RF) needle, an in-plane approach will be used for needle advancement. The needle will be advanced slowly until it reaches the inferior border of the rib. The needle will then be withdrawn 1-2 mm to ensure the needle tip is positioned adjacent to the intercostal nerve. The RF needle will then be connected to the RF generator for sensory testing. Stimulation parameters will be set at 50 Hz and 0.5-1V. The target location will be considered accurate if stimulation induces pain in the participant. Pulsed radiofrequency treatment will then be administered using the following parameters: voltage of 45V, frequency of 2 Hz, pulse width
Study NCT05761106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oculomotor Therapy
Description: It will consist exercise of a convergence technique and an accommodative technique.
Study NCT05761106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oculomotor Therapy
Description: It will consist exercise of a convergence technique and an accommodative technique.
Study NCT05761106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapy for Temporomandibular Disorder
Description: It will consist exercise of a ATM and cervical spine.
Study NCT05465018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Worst case hardware
Description: To test if software still works with an older smartphone
Study NCT05465018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Damaged lens
Description: To test if software is still working when the lens of the smartphone is damaged
Study NCT05465018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face or chest outside test frame
Description: To test software if the participants face or chest is outside the test frame
Study NCT05607511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics baby immunity formula (SIM03)
Description: Daily oral intake of a probiotics sachet
Study NCT06798662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine)
Description: The patient is positioned in either the lateral decubitus or sitting position, with the affected side facing upwards, ensuring adequate exposure of the targeted intercostal region. A high-frequency linear ultrasound transducer is placed transversely over the posterior lateral aspect of the targeted rib, using the vertebral column as a reference point. The transducer is then scanned laterally to identify the target rib, clearly visualizing the rib, intercostal muscles, and pleura. The intercostal nerve appears as a small hyperechoic structure located between the internal and innermost intercostal muscles. The needle is advanced until it contacts the inferior border of the rib. The needle is then slightly withdrawn and positioned between the internal and innermost intercostal muscles to avoid pleural puncture. After negative aspiration, 10 mL of 0.5% ropivacaine (or 133 mg of liposomal bupivacaine) combined with 10 mg of triamcinolone acetonide is injected slowly.
Study NCT06798662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)
Description: For the Paravertebral (PVB) block, a high-frequency linear ultrasound transducer was placed transversely, parallel to the spinous processes, approximately 2-3 cm lateral to the spinous process of the target thoracic vertebral segment. The position and angle of the transducer were adjusted to clearly visualize the transverse process (TP) and the axial view of the lamina of the target vertebra. In the ultrasound image, the transverse process appeared as a hyperechoic structure, typically with a characteristic acoustic shadow posterior to it. Subsequently, the transducer was slightly slid caudally, causing the transverse process and its acoustic shadow to gradually disappear from view. At this point, the ultrasound image revealed components of the paravertebral space (PVS), including the parietal pleura, the superior costotransverse ligament, and the intercostal fascia, which exhibited a heterogeneous mixed echogenicity. Using an in-plane technique, a puncture needle was advanced from lat
Study NCT06798662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal and Subserratus Plane (RISS) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)
Description: The RISS block is a composite nerve block technique that involves two injection sites: the inter-rhomboid plane and the sub-serratus plane. The selection of block plane was determined by the patient's specific location of pain.~Rhomboid Intercostal Plane Block (RIPB):~For the Rhomboid Intercostal Plane Block (RIPB), a high-frequency linear ultrasound transducer was initially positioned in a sagittal orientation, medial to the scapular border. It was then slightly rotated to obtain an oblique sagittal view (oblique paramedian sagittal view), located 1-2 cm lateral to the scapular border. Upon obtaining the appropriate ultrasound image, the following anatomical structures were identified sequentially, from superficial to deep: the trapezius muscle, the rhomboid muscles (specifically, the major rhomboid), the intercostal muscles (located between the ribs), the pleura, and the lung. The target injection plane was the fascial plane situated between the rhomboid muscle and the intercostal
Study NCT06798662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug (famciclovir and gabapentin)
Description: All patients will receive famciclovir and gabapentin. All participants will receive standard antiviral therapy with famciclovir 500 mg orally three times daily for 7 days. Gabapentin will be initiated at a typical starting dose of 300 mg per day, administered in three divided doses. The dosage may be gradually increased, as needed and tolerated, up to a maximum dose of 1800 mg per day.
Study NCT05359874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
Study NCT05096247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure
Description: This device is an RF device.
Study NCT06799091 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low frequency TENS
Description: Low TENS group participated in twelve sessions of electrical stimulation with low frequency (TENS, 10 Hz/200 μs) was applied with self-adhesive electrodes (size 9 × 5 cm,), in the paravertebral ganglionar region (from T1 to L2). The sessions took place at the same time of the day, lasted 30 min, in an acclimatized room (23 °C) and the intensity of the current was delivered at sensory-level intensity, adjusted every 5 min by the sensory threshold, during the 30 min as tolerated by each subject, but without motor contraction or pain reported by the subject.
Study NCT06799091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency TENS
Description: Low TENS group participated in twelve sessions of electrical stimulation with low frequency (TENS, 10 Hz/200 μs) was applied with self-adhesive electrodes (size 9 × 5 cm,), in the paravertebral ganglionar region (from T1 to L2). The sessions took place at the same time of the day, lasted 30 min, in an acclimatized room (23 °C) and the intensity of the current was delivered at sensory-level intensity, adjusted every 5 min by the sensory threshold, during the 30 min as tolerated by each subject, but without motor contraction or pain reported by the subject.
Study NCT06798480 — intervention group
Intervention type: OTHER
Intervention: Self-administered survey
Description: An anonymous self-administered online questionnaire hosted on LimeSurvey, lasting approximately 20 minutes, will be completed by participants. A panel of participants representative of the general population will be provided by the Selvitys Institute. In parallel, the self-administered questionnaire will also be distributed via posts on social media platforms (Facebook, YouTube, Instagram, TikTok, Snapchat, and X) over a period of three months.
Study NCT06793891 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ashwagandha root
Description: This substance is extracted from the root of the plant.
Study NCT06793891 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ashwagandha root and leaf
Description: This substance is extracted from both the root and leaves of the plant.
Study NCT06793891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The inert placebo does not contain any of the plant matter.
Study NCT06797986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVAC-E6E7 (low level)
Description: BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
Study NCT06797986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVAC-E6E7 (high level)
Description: BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
Study NCT06797986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVAC-E6E7 (RP2D)
Description: BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
Study NCT06798896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-817
Description: SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
Study NCT06798896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, bid
Study NCT05096247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Icon
Description: This device works with IPL (Intense Pulsed Light) handpieces.
Study NCT05047939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam-based TIVA
Description: In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
Study NCT05047939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-based TIVA
Description: In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
Study NCT06800196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNT-0916
Description: • KNT-0916 is an oral inhibitor of FGFR2.
Study NCT06318078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eCHIS
Description: The electronic Community health Information System (eCHIS) is a Government of Uganda owned application used by community health workers for quality health assessments and improved reporting. The eCHIS intervention allows for the registration of longitudinal profiles for client centered care as well as provides care guidance to aid decision making. For its users, the app has a task tab for schedule management and dashboards for performance help management and impact tracking by supervisors. This app is interoperable with national reporting tools such as DHIS2. The app has ten workflows including registration of households and new persons, death reporting, iCCM assessment, treatment and referral follow up, stock monitoring, data synchronization, pregnancy registration, ANC danger signs and follow up, family planning registration, and screening (tuberculosis, hypertension, sickle cell, tobacco use and net use).
Study NCT05295901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mKOAH application
Description: mobile app installed group
Study NCT06454383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging scans
Study NCT04717557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen (HBO2) 1-2 times daily for up to 10 times after amputation
Study NCT06454383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT06798792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PechaKucha technique
Description: The Discharge Education course was taught using the PechaKucha technique.
Study NCT06798792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TeachBack technique
Description: The Discharge Education course was taught using the TeachBack technique.
Study NCT06799104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyramidal training
Description: Pyramidal training prescription:Mode of exercise: aerobic interval training. Intensity: ranging from 20-80% from THR. Duration: 40 minutes per session.Frequency: Three sessions per week for 12 weeks.~The course of the program will be 2 sets of pyramidal training with 10 minutes for rest between them. Each set will be 5 levels of incremental and 5 levels of decremental aerobic exercise and each level 2 minutes on a treadmill.~1. Level one: will be set as a 20% walking of Karvonen formula.~2. Level two: will be set as a 30% running of Karvonen formula.~3. Level three: will be set as a 50%running of Karvonen formula.~4. Level four: will be set as a 70% running of Karvonen formula.~5. Level five: will be set as a 80% running of Karvonen formula.
Study NCT06799104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Mediterranean diet:~Meal Composition Main meals consumed daily should be a combination of three elements: cereals, vegetables and fruits, and a small quantity of legumes, beans or other (though not in every meal). Cereals in the form of bread, pasta, rice, couscous or bulgur (cracked wheat) should be consumed as one-two servings per meal. Vegetable consumption should amount to two or more servings per day, in raw form for at least one of the two main meals (lunch and dinner). Fruit should be considered as the primary form of dessert, with one-two servings per meal.
Study NCT06799104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Mediterranean diet:~Meal Composition Main meals consumed daily should be a combination of three elements: cereals, vegetables and fruits, and a small quantity of legumes, beans or other (though not in every meal). Cereals in the form of bread, pasta, rice, couscous or bulgur (cracked wheat) should be consumed as one-two servings per meal. Vegetable consumption should amount to two or more servings per day, in raw form for at least one of the two main meals (lunch and dinner). Fruit should be considered as the primary form of dessert, with one-two servings per meal.
Study NCT06798272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dialysisis with and without glucose in the dialysis
Description: there were assessed three consecutive hemodialysis sessions
Study NCT06798025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punctal dilation
Description: Patients were treated with punctal dilatation only.
Study NCT06798025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Punctal dilation and topical medication
Description: Patients were treated with a combination of punctal dilation and topical medication in the form of preservative-free steroid eye drops based on dexamethasone sodium phosphate (0.1%) and preservative-free artificial tears based on sodium hyaluronate, polyethylene, and propylene Glycol.
Study NCT06798025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Description: Patients were treated with a peri-punctual injection of Triamcinolone acetonide.
Study NCT06798116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: open flap debridement and demineralized freeze-dried bone allograft and mixed with liquid (PRF
Description: Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement and DFDBA and mixed with liquid (PRF)
Study NCT06798116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: defects will be treated with open flap debridement and liquid (PRF) mixed with denatured albumin gel (ALB-PRF) will be injected in periodontal intrabony defects
Description: Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, defects will be treated with open flap debridement and liquid (PRF) mixed with denatured albumin gel (ALB-PRF) will be injected in periodontal intrabony defects.
Study NCT06798116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and collagen membrane
Description: Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and collagen membrane
Study NCT06798116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement , DFDBA mixed with liquid (PRF) and ALB-PRF membrane.
Description: Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and ALB-PRF membrane.
Study NCT06798246 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Gemicitabin and cisplatin
Study NCT06798246 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: PD-1/PD-L1
Study NCT06798246 — intervention group
Intervention type: DRUG
Intervention: ADC
Description: ADC drug like RC48
Study NCT06798246 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy combined with immunotherapy
Description: Chemotherapy combined with immunotherapy
Study NCT05407129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family safety reporting intervention
Description: Family safety reporting intervention for patients/families
Study NCT06800144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate synchronized motor imagery music therapy
Description: Participants included in this group will listen a metronome sound in a rhythm synchronized with their heart rate.